FDA Approves Selpercatinib for RET Fusion-Positive Solid Tumors
The FDA has granted traditional approval for selpercatinib, targeting locally advanced or metastatic RET fusion-positive solid tumors.
Asset / Drug
Drug and asset intelligence for selpercatinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.